Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

IND.225 - A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker

The main purpose of this study is to find out if tumour CT texture analysis (enhancing of images in ultra-fine detail not visible to the human eye) can predict time to progression and response more accurately.

IND.231 - A Phase I/II Study of CX5461

The main purpose of this study is to determine the best dose of CX5461 in patients with solid tumours (phase I) and breast cancer with known tumour DNA abnormalities (phase II), and to investigate the safety and toxicity of CX5461, as well as response and clinical benefit of this therapy. Additional research will investigate what effects CX5461 has on cancer cells and will explore the relationship between certain tumour DNA abnormalities and outcomes of CX5461 treatment.